These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33724251)

  • 1. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial.
    Adler LA; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    Int Clin Psychopharmacol; 2021 May; 36(3):117-125. PubMed ID: 33724251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
    Findling RL; Adler LA; Spencer TJ; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):80-89. PubMed ID: 30694697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.
    Koblan KS; Hopkins SC; Sarma K; Jin F; Goldman R; Kollins SH; Loebel A
    Neuropsychopharmacology; 2015 Nov; 40(12):2745-52. PubMed ID: 25948101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.
    Grilo CM; McElroy SL; Hudson JI; Tsai J; Navia B; Goldman R; Deng L; Kent J; Loebel A
    CNS Spectr; 2021 Oct; 26(5):481-490. PubMed ID: 32423512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial.
    McElroy SL; Hudson JI; Grilo CM; Guerdjikova AI; Deng L; Koblan KS; Goldman R; Navia B; Hopkins S; Loebel A
    J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Placebo-Controlled Laboratory Classroom Study of the Efficacy and Safety of Dasotraline in Children With ADHD.
    Wigal S; Tsai J; Bates JA; Sarma K; Tortorich D; Zhu H; Goldman R
    J Atten Disord; 2022 Aug; 26(10):1357-1368. PubMed ID: 35048745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study.
    Wigal SB; Hopkins SC; Koblan KS; Childress A; Kent JM; Tsai J; Hsu J; Loebel A; Goldman R
    J Atten Disord; 2020 Jan; 24(2):192-204. PubMed ID: 31375051
    [No Abstract]   [Full Text] [Related]  

  • 8. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    Wigal TL; Newcorn JH; Handal N; Wigal SB; Mulligan I; Schmith V; Konofal E
    CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 15. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
    Dittmann RW; Cardo E; Nagy P; Anderson CS; Adeyi B; Caballero B; Hodgkins P; Civil R; Coghill DR
    CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
    Hopkins SC; Sunkaraneni S; Skende E; Hing J; Passarell JA; Loebel A; Koblan KS
    Clin Drug Investig; 2016 Feb; 36(2):137-46. PubMed ID: 26597180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.